Paula de Robles
Overview
Explore the profile of Paula de Robles including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
324
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Daun J, Capozzi L, Dhruva T, Urgoiti G, McDonough M, McLaughlin E, et al.
Neurooncol Pract
. 2025 Feb;
12(1):131-142.
PMID: 39917754
Background: To address the lack of access to supportive cancer care resources, the purpose of this study was to examine the feasibility of a tailored exercise program for neuro-oncology patients....
2.
Hansen M, Kapadia R, Alikhani K, de Robles P, Hahn C
Can J Neurol Sci
. 2024 Sep;
:1-7.
PMID: 39297442
Background: Autoimmune encephalidities (AIE) are becoming an increasingly recognized cause of encephalitis. While diagnosis and acute management are well described, information on long-term management and outcomes is limited. Given this,...
3.
Latzer P, Zelba H, Battke F, Reinhardt A, Shao B, Bartsch O, et al.
Nat Commun
. 2024 Aug;
15(1):6870.
PMID: 39127809
Current treatment outcome of patients with glioblastoma (GBM) remains poor. Following standard therapy, recurrence is universal with limited survival. Tumors from 173 GBM patients are analysed for somatic mutations to...
4.
Hahn C, Budhram A, Alikhani K, AlOhaly N, Beecher G, Blevins G, et al.
Can J Neurol Sci
. 2024 Feb;
:1-21.
PMID: 38312020
Autoimmune encephalitis is increasingly recognized as a neurologic cause of acute mental status changes with similar prevalence to infectious encephalitis. Despite rising awareness, approaches to diagnosis remain inconsistent and evidence...
5.
Faye M, Easaw J, de Robles P, Agnihotram R, Torres-Vasquez A, Lamonde F, et al.
Neurooncol Adv
. 2023 Sep;
5(1):vdad106.
PMID: 37771465
Background: The overall prognosis of glioblastoma (GBM) remains dismal, particularly for patients with unmethylated O6-methylguanine-DNA-methyltransferase () promoter. In this phase II trial, we tested the combination of the antiangiogenic agent...
6.
Hsu P, Folkman F, Ghosh S, de Robles P, Leckie C, Dersch-Mills D, et al.
J Oncol Pharm Pract
. 2020 Oct;
27(7):1723-1729.
PMID: 33121351
Background: Adult glioblastoma patients receiving standard radiation therapy and concurrent temozolomide chemotherapy have a median survival of 14.6 months. Based on the pivotal trial data by Stupp et al., temozolomide...
7.
Boyko M, Au K, Casault C, de Robles P, Pfeffer G
J Neurol
. 2020 Jan;
267(4):1137-1146.
PMID: 31912210
Background: Contactin-associated protein-like 2 (CASPR2) autoantibody disease has a variable clinical phenotype. We present a case report and performed a systematic review of the literature to summarize: (1) the clinical...
8.
de Robles P, Fiest K, Frolkis A, Pringsheim T, Atta C, St Germaine-Smith C, et al.
Neuro Oncol
. 2014 Oct;
17(6):776-83.
PMID: 25313193
Background: Primary brain tumors are a heterogeneous group of benign and malignant tumors arising from the brain parenchyma and its surrounding structures. The epidemiology of these tumors is poorly understood....
9.
Mah J, Warner J, Hall R, Smith E, Steeves T, Donner E, et al.
Can J Neurol Sci
. 2013 Jun;
40(4 Suppl 2):S60-1.
PMID: 23787271
No abstract available.
10.
Hogan D, Warner J, Patten S, Godlovitch G, Mehina E, Dagenais L, et al.
Can J Neurol Sci
. 2013 Jun;
40(4 Suppl 2):S5-22.
PMID: 23787268
No abstract available.